I-CBP112 hydrochloride is a potent and selective inhibitor of the bromodomains of CREB-binding protein (CBP) and E1A-binding protein p300 (EP300). It is primarily used in research settings to study its effects on epigenetic regulation, histone acetylation, and gene expression. This compound is valuable in understanding the mechanisms of diseases such as cancer, inflammation, neurological disorders, and cardiovascular conditions, where CBP/p300 bromodomains are involved in transcriptional activation and chromatin remodeling. Researchers utilize I-CBP112 hydrochloride to explore potential therapeutic strategies by modulating enhancer functions and gene activation pathways. Its application extends to preclinical studies aimed at developing targeted treatments for conditions linked to abnormal epigenetic modifications.